protooncogen
human
epiderm
growth
factor
receptor
sequenc
homolog
rat
neu
genecod
protein
neu
origin
detect
rat
neuroblastoma
tyrosin
kinas
receptor
belong
epiderm
growth
factor
receptor
compos
extracellular
transmembran
intracellular
breast
cancer
common
cancer
among
women
western
world
protein
overexpress
case
breast
becom
attract
target
antigen
ag
select
overexpress
malign
cell
ii
immun
respons
frequent
found
patient
breast
indic
selftoler
broken
human
although
overexpress
often
associ
poor
permit
novel
therapi
direct
human
monoclon
antibodi
ab
trastuzumab
possibl
best
howev
women
sooner
later
develop
resist
warrant
search
therapeut
cytotox
lymphocyt
ctl
import
role
host
defens
virus
intracellular
bacteria
reason
vaccin
capabl
induc
strong
ctl
respons
becom
major
goal
field
tumor
immun
replicationdefici
adenovirus
adv
found
effect
vaccin
vector
mimic
natur
infect
stimul
innat
immun
respons
lead
develop
effect
tcell
respons
vaccineencod
therefor
genet
vaccin
base
upon
recombin
adv
use
immun
infecti
diseas
human
immunodefici
vaccin
ovalbumin
ova
express
recombin
adv
stimul
effici
ovaspecif
ctl
lead
protect
viru
addit
recombin
adv
also
appli
induct
antitumor
immun
studi
recombin
adv
vaccin
shown
induc
effici
prophylact
antitumor
immun
exampl
vaccin
tyrosinaserel
proteinexpress
adv
induc
tyrosinaserel
proteinspecif
tcell
respons
lead
prevent
immun
tyrosinaserel
proteinexpress
reduct
melanoma
relaps
adv
vaccin
stimul
ab
ctl
respons
lead
prevent
antitumor
immun
wildtyp
howev
therapeut
efficaci
remain
controversi
exampl
ineffect
adv
vaccin
demonstr
even
administ
earli
two
tumor
cell
seed
wildtyp
mice
convers
investig
shown
recombin
vaccin
effici
erad
advanc
establish
murin
breast
cancer
wildtyp
studi
assess
tcell
respons
antitumor
immun
deriv
vaccin
two
recombin
adv
advova
express
ova
ovaexpress
melanoma
breast
cancer
respect
addit
compar
therapeut
effici
ab
therapi
vaccin
combin
two
wellestablish
breast
cancer
transgen
tg
mice
monoclon
ab
mous
ab
reactiv
rat
oncogenencod
molecul
obtain
american
tissu
type
collect
rockvil
md
biotinlabel
ab
obtain
pharmingen
canada
mississauga
ontario
canada
fluorescein
isothiocyan
fitc
conjug
ab
specif
phycoerythrin
pe
label
tetram
pelabel
peptid
pdslrdlsvf
tetram
obtain
beckman
coulter
san
diego
ca
nih
tetram
facil
bethesda
md
respect
major
histocompat
complex
class
restrict
ovai
siinfekl
peptid
irrelev
peptid
feqntaqp
synthes
multipl
peptid
system
san
diego
ca
highli
lung
metastat
ovatransfect
melanoma
cell
line
gener
mous
breast
cancer
cell
line
deriv
spontan
breast
cancer
tumor
obtain
dr
kipp
univers
california
san
diego
ca
natur
killer
nk
sensit
tumor
cell
line
obtain
american
tissu
cell
collect
rockvil
md
femal
wildtyp
mice
fvbnjtgn
mmtvneu
fvbneun
tg
mice
express
rat
neu
control
mous
mammari
tumor
viru
promot
obtain
jackson
laboratori
bar
harbor
mice
hous
anim
facil
saskatoon
cancer
center
anim
experi
carri
accord
canadian
council
anim
care
guidelin
construct
recombin
advexpress
ova
advova
perform
insert
ova
gene
clone
pacova
vector
obtain
dr
bevan
univers
washington
seattl
washington
pshuttl
vector
stratagen
la
jolla
ca
form
plpaovaexpress
ova
gene
figur
pmeidigest
shuttl
vector
cotransform
escherichia
coli
cell
alreadi
contain
backbon
vector
increas
effici
homolog
recombin
form
recombin
advova
recombin
advova
vector
linear
paci
digest
transfect
cell
use
lipofectamin
gibcobrl
burlington
ontario
canada
gener
advova
recombin
express
rat
neu
gene
control
advnul
without
insert
transgen
figur
previous
construct
recombin
adv
amplifi
cell
purifi
seri
cesium
chlorid
ultracentrifug
gradient
store
use
lymphocyt
drainag
lymph
node
mice
sc
immun
advova
pfu
per
mous
harvest
day
immun
stain
ab
ab
analyz
flow
cytometri
assess
kill
activ
perform
chromiun
assay
lymphocyt
deriv
immun
mous
drainag
lymph
node
use
target
effector
cell
respect
target
cell
radiolabel
cultur
cell
h
cultur
medium
presenc
sodium
chromat
mci
amersham
arlington
height
il
wash
twice
phosphatebuff
salin
approxim
label
target
cell
per
triplic
well
mix
effector
cell
variou
effector
e
target
cell
ratio
incub
h
percentag
specif
lysi
calcul
experiment
cpm
maxim
cpm
spontan
cpm
releas
absenc
effector
cell
specif
lysi
maxim
cpm
releas
determin
lysi
target
cell
triton
mice
immun
iv
inject
advova
pfu
per
mous
differ
day
immun
mous
peripher
blood
stain
fitcconjug
ab
peconjug
tetram
min
room
temperatur
analyz
flow
cytometri
fvbneun
tg
mice
immun
iv
inject
pfu
per
mous
eleven
day
immun
mous
peripher
blood
incub
fitcconjug
ab
pelabel
peptid
tetram
min
room
temperatur
analyz
flow
cytometri
vivo
cytotox
assay
mous
spleen
cell
puls
ovai
peptid
strongli
label
carboxylfluorescein
succinimidyl
ester
cfse
cfsehigh
serv
ovaspecif
target
cell
wherea
spleen
cell
puls
irrelev
peptid
weakli
label
cfse
cfselow
serv
nonspecif
control
target
cell
respect
eleven
day
follow
immun
advova
immun
mice
iv
inject
cfsehigh
cfselow
mixtur
splenocyt
target
sixteen
hour
target
cell
deliveri
spleen
recipi
mice
remov
rel
proport
cfsehigh
cfselow
target
cell
remain
spleen
analyz
flow
cytometri
three
type
anim
studi
conduct
first
type
anim
studi
perform
evalu
prevent
antitumor
immun
wildtyp
mice
mice
per
group
sc
vaccin
advova
pfu
per
mous
eleven
day
immun
mice
sc
inject
right
thigh
tumor
cell
cell
per
mous
assess
cellular
mechan
advovainduc
antitumor
immun
mice
ip
inject
ab
mg
per
mous
deplet
cell
nk
cell
day
advova
immun
one
day
ab
treatment
mice
challeng
sc
inject
cell
per
mous
ab
treatment
repeat
everi
day
total
five
time
assess
longterm
immun
mice
also
sc
inocul
cell
per
mous
day
immun
second
type
anim
studi
perform
evalu
prevent
breast
carcinogenesi
tg
fvbneun
mice
mice
per
group
age
month
vaccin
sc
pfu
per
mous
interv
total
five
vaccin
spontan
breast
tumor
develop
monitor
weekli
third
type
anim
studi
design
evalu
therapeut
antitumor
immun
fvbneun
mice
mice
per
group
sc
inject
cell
per
mous
cell
mous
monitor
weekli
tumor
growth
measur
two
perpendicular
diamet
use
calip
tumor
volum
calcul
use
formula
va
largest
b
smallest
repres
tumor
grew
size
earli
stage
around
day
tumor
cell
inject
well
establish
around
day
tumor
cell
inject
tumorbear
fvbneun
tg
mice
sc
inject
pfu
per
mous
interv
total
three
time
mimic
clinic
administr
trastuzumab
patient
load
dose
mg
trastuzumab
per
kg
patient
bodi
weight
tumorbear
mice
also
ip
inject
ab
dose
mg
mous
bodi
weight
everi
day
total
five
time
anoth
tumorbear
mous
group
mice
treat
ab
tumor
growth
monitor
daili
day
ethic
reason
mice
tumor
achiev
size
volum
kill
statist
analys
conduct
use
prism
softwar
graphpad
softwar
san
diego
ca
perform
logrank
test
compar
mous
surviv
group
determin
signific
differ
group
student
ttest
perform
pvalu
consid
statist
assess
cellular
immun
respons
iv
immun
wildtyp
mice
recombin
ovaexpress
adenoviru
advova
evalu
ovaspecif
tcell
respons
mous
peripher
blood
use
ab
tetram
stain
flow
cytometri
found
advova
vaccin
stimul
sustain
ovaspecif
tcell
respons
account
total
tcell
popul
figur
significantli
larger
mice
immun
control
advnul
p
ovaspecif
tcell
respons
peak
day
immun
declin
slowli
assess
function
effect
cell
perform
vivo
cytotox
assay
adopt
transfer
ovai
peptidepuls
splenocyt
strongli
label
cfse
cfsehigh
well
control
peptid
splenocyt
weakli
label
cfse
cfselow
recipi
mice
vaccin
advova
expect
substanti
loss
cfsehigh
ovai
peptidepuls
cell
advovaimmun
mice
wherea
littl
cytotox
induc
mice
immun
control
advnul
figur
p
indic
advova
vaccin
effici
stimul
tcell
differenti
function
ovaspecif
ctl
effector
assess
potenti
advstimul
nk
respons
lymphocyt
mice
sc
immun
advova
harvest
drainag
lymph
node
day
immun
analyz
nk
activ
kill
activ
flow
cytometri
vitro
cytotox
assay
respect
shown
figur
proport
activ
nk
cell
significantli
greater
adv
advnul
advova
treat
mice
compar
control
mice
p
addit
nk
cell
deriv
adv
advnul
advova
treat
mice
display
stronger
kill
activ
tumor
cell
nk
cell
control
wildtyp
mice
p
figur
indic
advova
stimul
nonspecif
nk
cell
respons
assess
prevent
antitumor
immun
aboveimmun
mice
sc
challeng
ovaexpress
melanoma
day
subsequ
immun
found
mice
immun
control
advnul
die
tumor
within
day
subsequ
tumor
cell
challeng
wherea
mice
immun
advova
tumor
free
figur
indic
advova
stimul
prevent
antitumor
immun
mice
assess
cellular
mechan
antitumor
immun
treat
immun
mice
ab
deplet
nk
cell
respect
tumor
cell
challeng
demonstr
mice
treatment
ab
antink
ab
lost
antitumor
protect
indic
advovainduc
antitumor
immun
mainli
mediat
ctl
assess
longterm
immun
advovaimmun
mice
challeng
sc
inocul
tumor
cell
day
immun
found
none
immun
mice
grew
tumor
figur
indic
advova
vaccin
also
induc
longterm
antitumor
immun
tg
fvbneun
mice
neuspecif
selfimmun
spontan
develop
multipl
breast
cancer
differ
size
differ
age
figur
b
tg
mice
extens
use
evalu
assess
tcell
respons
peripher
blood
sampl
mice
immun
advneu
harvest
day
immun
stain
ab
peptid
tetram
analyz
flow
cytometri
found
tcell
respons
account
total
tcell
popul
figur
indic
stimul
tcell
respons
tg
fvbneun
mice
immun
toler
determin
whether
cellular
immun
respons
could
reduc
breast
carcinogenesi
tg
fvbneun
mice
age
month
vaccin
sc
interv
total
four
vaccin
shown
figur
vaccin
protect
mice
breast
carcinogenesi
induc
signific
delay
tumor
format
mice
compar
control
advnul
vaccin
p
indic
vaccin
partli
overcom
immun
toler
reduc
breast
carcinogenesi
tg
fvbneun
mice
assess
potenti
therapeut
effect
tg
mice
repeat
experi
use
advher
vaccin
tumorbear
tg
fvbneun
mice
selfimmun
toler
found
vaccin
mice
bear
earli
stage
breast
cancer
die
cancer
within
day
initi
vaccin
though
mous
surviv
prolong
p
figur
demonstr
ab
potent
therapeut
effect
establish
tumor
assess
therapeut
effici
repeat
experi
use
ab
tumorbear
tg
fvbneun
mice
tumor
cell
grew
aggress
figur
found
vaccin
mice
bear
earli
stage
breast
cancer
becam
tumor
free
figur
wherea
mice
bear
wellestablish
tumor
surviv
though
mice
longer
surviv
p
figur
interestingli
found
mice
bear
wellestablish
tumor
free
tumor
mice
treat
vaccin
combin
ab
therapi
wherea
remain
tumorbear
mice
longer
surviv
p
indic
vaccin
recombin
adenovir
vector
reduc
breast
carcinogenesi
also
provid
adjuv
effect
ab
therapi
erad
wellestablish
breast
cancer
tg
fvbneun
mice
immun
toler
convent
cancer
therapi
includ
surgeri
radiat
therapi
chemotherapi
demonstr
consider
clinic
success
past
year
howev
tumorfre
surviv
alway
accomplish
exampl
surgeri
radiat
therapi
quit
effect
treatment
local
tumor
often
palli
role
treatment
dissemin
diseas
chemotherapi
remain
treatment
modal
choic
sever
toxic
sideeffect
often
limit
use
identif
tumorassoci
ag
tumorspecif
tcell
respons
cancer
patient
led
develop
immunotherapi
aim
augment
antitumor
immun
respons
antitumor
immunotherapi
includ
activ
immunotherapi
use
variou
antitumor
stimul
patient
antitumor
ctl
respons
adopt
immunotherapi
infus
antitumor
monoclon
ab
tumorspecif
tumorinfiltr
origin
murin
monoclon
antibodi
inhibit
tumor
growth
trastuzumab
human
monoclon
ab
direct
extracellular
domain
use
combin
chemotherapi
approv
fda
metastat
overexpress
breast
preclin
studi
demonstr
interest
properti
trastuzumab
intern
degrad
inhibit
cellcycl
progress
via
inhibit
mitogenactiv
protein
kinas
suppress
antiapoptot
phosphatidylinositol
akt
abdepend
cellular
clinic
studi
shown
approxim
one
third
patient
advanc
breast
cancer
respond
trastuzumab
trastuzumabbas
therapi
also
shown
effect
adjuv
neoadjuv
set
manag
earli
stage
breast
howev
one
major
limit
trastuzumab
immunotherapi
develop
ab
resist
usual
within
year
begin
treatment
metastat
schemat
resist
trastuzumab
may
deriv
truncat
activ
form
receptor
lack
trastuzumabbind
extracellular
domain
ii
constitut
activ
downstream
element
make
activ
pathway
independ
receptor
andor
iii
bypass
activ
anoth
transmembran
addit
risk
cardiac
toxic
especi
patient
previous
treat
may
also
limit
use
trastuzumab
sinc
immun
respons
frequent
found
patient
breast
shown
preclin
model
immun
respons
associ
slower
tumor
develop
earli
stage
observ
togeth
report
efficaci
resist
passiv
trastuzumab
therapi
motiv
develop
variou
combinatori
immunotherapi
among
combin
therapeut
monoclon
antibodi
trastuzumab
variou
antitumor
vaccin
tumor
cell
dendrit
cell
dna
peptid
protein
viral
vector
promis
avenu
combin
compar
passiv
immunotherapi
trastuzumab
vaccin
stimul
preexist
immun
respons
offer
sever
advantag
includ
fewer
iter
inject
ii
potenti
broader
use
patient
express
differ
level
iii
establish
memori
immun
respons
capabl
prevent
diseas
recurr
clinic
trial
demonstr
vaccin
could
incorpor
trastuzumab
result
repres
first
clinic
evid
potenti
benefit
minim
toxic
may
deriv
combin
immunotherapi
also
demonstr
combin
trastuzumab
follow
peptid
vaccin
safe
one
remark
featur
advbas
vaccin
abil
induc
except
high
sustain
frequenc
transgen
productspecif
tcell
respons
unlik
induc
subunit
vaccin
carrier
dna
vaccin
poxviru
vector
contract
initi
ctl
studi
also
demonstr
advova
vaccin
induc
sustain
ctl
respons
due
persist
ag
stimul
consist
previou
report
elucid
replicationdefect
adv
vector
genom
similar
wildtyp
adv
vector
acquir
natur
infect
replicationdefect
adv
vector
found
muscl
site
inocul
liver
lymphat
tissu
experiment
demonstr
vaccin
stimul
ab
ctl
respons
prevent
antitumor
immun
wildtyp
howev
abl
reduc
breast
carcinogenesi
tg
mice
selfimmun
toler
though
surviv
studi
demonstr
induc
function
cell
also
nk
respons
lead
protect
antitumor
immun
howev
cell
nk
cell
major
role
immun
consist
recent
report
wan
previous
demonstr
vaccin
dendrit
cell
engin
express
result
signific
delay
tumor
format
howev
despit
stronger
immun
respons
dna
vaccin
reduc
breast
present
studi
demonstr
vaccin
significantli
reduc
breast
carcinogenesi
tg
fvbneun
mice
selfimmun
toler
consist
anoth
recent
report
berzofski
et
therapeut
efficaci
adv
cancer
remain
controversi
exampl
adv
vaccin
found
ineffect
even
administ
earli
two
seed
tumor
cell
wildtyp
mice
convers
also
demonstr
recombin
vaccin
effici
erad
advanc
establish
murin
breast
cancer
wildtyp
studi
show
vaccin
littl
therapeut
effect
preexist
tumor
slightli
delay
breast
tumor
growth
cure
tumor
tg
fvbneun
mice
even
though
earli
stage
differ
therapeut
effect
seen
studi
previou
may
deriv
use
differ
type
mice
studi
use
tg
fvbneun
mice
immun
toler
wherea
myun
et
al
use
wildtyp
comparison
howev
ab
therapi
much
effect
sinc
cure
earli
stage
tumor
tg
fvbneun
mice
fail
erad
wellestablish
tumor
bocangel
et
demonstr
combinatori
synergi
induc
vaccin
express
tumor
suppressor
gene
melanoma
differentiationassoci
trastuzumab
delay
growth
human
breast
cancer
nude
mice
interestingli
first
time
demonstr
combinatori
immunotherapi
ab
vaccin
capabl
erad
tg
fvbneun
mice
bear
wellestablish
breast
cancer
significantli
prolong
surviv
remain
tumorbear
mice
indic
synergist
effect
vaccin
capabl
stimul
ctl
nonspecif
nk
cell
respons
ab
therapi
wellestablish
tumor
tg
fvbneun
mice
immun
toler
taken
togeth
demonstr
adenovir
vector
vaccin
stimul
ctl
nk
cell
respons
provid
adjuv
effect
ab
therapi
result
suggest
adjuv
effect
ab
therapi
combinatori
immunotherapi
trastuzumab
vaccin
may
use
new
therapeut
strategi
treatment
advanc
breast
cancer
